Amedeo Smart

Free Medical Literature Service

 

Amedeo

Migraine
  Free Subscription

Articles published in
Headache
    April 2026
  1. HOULE TT, Sexton K, Lebowitz A, Chtay I, et al
    Stress and fasting for inducing migraine attacks: A randomized 2 x 2 factorial crossover trial.
    Headache. 2026 Apr 23. doi: 10.1111/head.70105.
    >> Share

  2. JOSHI S, Tassorelli C, Matharu M, Alsaadi T, et al
    Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.
    Headache. 2026 Apr 22. doi: 10.1111/head.70107.
    >> Share

  3. PERNOT P, Bani-Sadr A, Ong E, Cho TH, et al
    Discriminating migraine aura from transient ischemic attack using MRI-based oxygen metabolism mapping: A preliminary study.
    Headache. 2026 Apr 22. doi: 10.1111/head.70112.
    >> Share

  4. ORR SL
    Retrofitted adult interventions aren't good enough: Why children and adolescents deserve tailored evidence-based care for migraine in the emergency department.
    Headache. 2026 Apr 10. doi: 10.1111/head.70092.
    >> Share

  5. DE OLIVEIRA GC, Baggio DF, Lejeune VBP, Quinelato LS, et al
    Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine-like responses in rats in a sex-specific manner.
    Headache. 2026 Apr 9. doi: 10.1111/head.70099.
    >> Share

  6. SHINAN-ALTMAN S, Hamama-Raz Y
    Cognitive and emotional mechanisms underlying migraine quality of life.
    Headache. 2026 Apr 9. doi: 10.1111/head.70102.
    >> Share

  7. ZHANG P, Xie X, Li Y, Wang Y, et al
    Long-term air pollution exposure and incident migraine in middle aged and older adults: A population-based study.
    Headache. 2026 Apr 6. doi: 10.1111/head.70093.
    >> Share

  8. KORN TF, Bernstein C
    Migraine across the menopausal transition and beyond: A narrative review.
    Headache. 2026 Apr 3. doi: 10.1111/head.70071.
    >> Share

  9. KLEINE-BORGMANN J, Schmidt K, Bingel U
    Beyond concealment: Translating placebo research into migraine care.
    Headache. 2026 Apr 3. doi: 10.1111/head.70091.
    >> Share

  10. TOURIGNY-RUEL G, Bailey B, Jean-Charles S, Gravel J, et al
    Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department.
    Headache. 2026 Apr 3. doi: 10.1111/head.70087.
    >> Share

  11. GARCIA-CASTILLO MC, Sierra-Mencia A, Caronna E, Toledo-Alfocea D, et al
    Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study.
    Headache. 2026 Apr 1. doi: 10.1111/head.70086.
    >> Share

  12. MOSKATEL LS, Slusky DJG
    The state of insurance coverage of calcitonin gene-related peptide-targeted medications and its impact on the implementation of the American Headache Society's 2024 consensus statement: An interrupted time-series analysis.
    Headache. 2026;66:801-812.
    >> Share

    March 2026
  13. JUNG DE, Cho S, Ha WS, Shin HJ, et al
    Chronotype in migraine and tension-type headache: A population study.
    Headache. 2026 Mar 28. doi: 10.1111/head.70070.
    >> Share

  14. VANDERPLUYM JH
    The status of status migrainosus: Exploring conceptual and operational limitations of International Classification of Headache Disorders criteria.
    Headache. 2026 Mar 27. doi: 10.1111/head.70095.
    >> Share

  15. ROBBLEE J, Smith JH, Ahmad S, Geiser R, et al
    Redefining status migrainosus: A narrative review.
    Headache. 2026 Mar 27. doi: 10.1111/head.70075.
    >> Share

  16. BENKLI B
    Editorial: Migraine as a marker of maternal morbidity.
    Headache. 2026 Mar 20. doi: 10.1111/head.70090.
    >> Share

  17. SJONNESEN K, Noel M, Pringsheim T, Patten SB, et al
    Maternal and child mental health and incident migraine in adolescence: An "All Our Families" prospective cohort study.
    Headache. 2026 Mar 19. doi: 10.1111/head.70078.
    >> Share

  18. BERGER CT, Villena FB, Vogt SB, Heydrich L, et al
    Delayed urticaria during treatment with anti-CGRP monoclonal antibodies in migraine.
    Headache. 2026 Mar 15. doi: 10.1111/head.70082.
    >> Share

  19. TRAM MT, Cheng N, Jicha C
    Differential impact of migraine on severe maternal morbidity and postpartum readmissions: Insights from a national cohort study.
    Headache. 2026 Mar 13. doi: 10.1111/head.70080.
    >> Share

  20. CAO B, Chen Q, Liu Y, Wu R, et al
    Microneedles for the treatment of migraine and orofacial pain: A narrative review.
    Headache. 2026 Mar 13. doi: 10.1111/head.70074.
    >> Share

  21. HIKITA T, Kudo T, Ogawa Y, Nakamoto N, et al
    A study of migraine-like headache caused by topical aryl hydrocarbon receptor agonist tapinarof.
    Headache. 2026 Mar 6. doi: 10.1111/head.70077.
    >> Share

  22. DORSEY E, Robblee J
    Epidemiology and characteristics of status migrainosus in a tertiary headache clinic: A retrospective cohort study.
    Headache. 2026 Mar 6. doi: 10.1111/head.70067.
    >> Share

  23. SILBERSTEIN S, Rapoport AM
    Novel optimization of multi-mechanistic approaches for the acute treatment of a migraine attack: A review.
    Headache. 2026 Mar 4. doi: 10.1111/head.70051.
    >> Share

  24. TOL CHM, Visscher CM, van der Wal AC, Su N, et al
    Psychosocial factors as predictors of headache chronification: A systematic review and meta-analysis of longitudinal studies.
    Headache. 2026;66:755-767.
    >> Share

  25. ZAVALA LJ, Gil Ramirez A, Vetvik KG, Jensen RH, et al
    Headache in individuals undergoing hormone therapy for gender transition: A cross-sectional, observational study.
    Headache. 2026;66:725-732.
    >> Share

    February 2026
  26. HUTCHINSON S, Johnston E, Nicholson RA, Reed ML, et al
    Unmet treatment needs in migraine: Results of the OVERCOME (US) study.
    Headache. 2026 Feb 20. doi: 10.1111/head.70043.
    >> Share

  27. YANG PH, Zhang N, Chao CJ, Lopez-Jimenez F, et al
    Higher artificial intelligence-ECG atrial fibrillation prediction model output and estimated physiologic aging predict higher risk of adverse vascular events in patients with migraine.
    Headache. 2026 Feb 20. doi: 10.1111/head.70062.
    >> Share

  28. LIPTON RB, Dodick DW, Davis L, Nahas SJ, et al
    Integrating gepants into clinical practice for the acute treatment of migraine.
    Headache. 2026 Feb 18. doi: 10.1111/head.70047.
    >> Share

  29. NITSCHE L, Helbach J, Stubenrauch S, Lakeberg M, et al
    The association between posttraumatic stress disorder and migraine: A systematic review.
    Headache. 2026 Feb 18. doi: 10.1111/head.70058.
    >> Share


  30. Correction to "Migraine and air pollution: A systematic review".
    Headache. 2026 Feb 12. doi: 10.1111/head.70053.
    >> Share

  31. GRAVES KS, To J, Paige H, Kennedy AG, et al
    Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention.
    Headache. 2026 Feb 12. doi: 10.1111/head.70057.
    >> Share

  32. CHARLESTON L 4TH, Armand CE, Monteith TS, O'Brien HL, et al
    Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials.
    Headache. 2026 Feb 6. doi: 10.1111/head.70034.
    >> Share

  33. TOURLAS K, Ilangovan S, White C, Irwin SL, et al
    Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents.
    Headache. 2026 Feb 6. doi: 10.1111/head.70033.
    >> Share

  34. GERARD B, Praudel H, Lanteri-Minet M, Van Obberghen E, et al
    First successful protocol for desensitization to eptinezumab.
    Headache. 2026;66:556-559.
    >> Share

    January 2026
  35. NWAOBI SE
    Useful considerations for treating migraine in patients with autism.
    Headache. 2026 Jan 29. doi: 10.1111/head.70054.
    >> Share

  36. CHEN H, Li Y
    Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Headache. 2026 Jan 28. doi: 10.1111/head.70049.
    >> Share

  37. BUSE DC, Videnieks LA, Charles K, Lozach K, et al
    Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi-source dataset, observational cohort study.
    Headache. 2026 Jan 21. doi: 10.1111/head.70026.
    >> Share

  38. AILANI J, Okonkwo R, Johnston E, Hochstetler H, et al
    Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study.
    Headache. 2026 Jan 6. doi: 10.1111/head.70014.
    >> Share

  39. ZELDICH D, Calderon N, Goor-Aryeh I, Lichtenstein GR, et al
    Case report: Treatment of temporomandibular joint disorder pain with V3 nerve block procedure.
    Headache. 2026;66:332-335.
    >> Share

  40. SHIN L, Mentz O, Gelfand AA, de Prado BM, et al
    Gepants for headache prevention in children and adolescents: A multicenter chart review study.
    Headache. 2026;66:239-248.
    >> Share

  41. PATEL EJ, Sharon JD, Levin M, Luebke AE, et al
    Calcitonin gene-related peptide in the audiovestibular system.
    Headache. 2026;66:278-285.
    >> Share

    December 2025
  42. CHENG N, Anderson CC, Zhang N, VanderPluym JH, et al
    Remote electrical neuromodulation for reducing procedural pain in patients with chronic migraine receiving onabotulinumtoxinA injections: A randomized sham-controlled study.
    Headache. 2025 Dec 31. doi: 10.1111/head.70032.
    >> Share

  43. SCHUSTER NM, Wallace MS, Marcotte TD, Buse DC, et al
    Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.
    Headache. 2025 Dec 30. doi: 10.1111/head.70025.
    >> Share

  44. GRANT TEJADA MP, Klomhaus AM, Ortiz R, Tibbe TD, et al
    Migraine prevalence and phenotype in autism: A retrospective cohort study using a US National Health Survey and large academic health system electronic health record.
    Headache. 2025 Dec 29. doi: 10.1111/head.70035.
    >> Share

  45. SCHINDLER EAD, Gottschalk CH, Pittman BP, D'Souza DC, et al
    Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.
    Headache. 2025 Dec 29. doi: 10.1111/head.70024.
    >> Share

  46. MEHNERT J, Scutelnic A
    Migraine is a disorder of function: No evidence for structural alterations within the central nervous system in migraine.
    Headache. 2025 Dec 16. doi: 10.1111/head.70010.
    >> Share

  47. PARDO K, Mermelstein M, Tsur G, Yust-Katz S, et al
    Do patients with migraine and obesity receive different treatments? Insights from real-world data.
    Headache. 2025 Dec 15. doi: 10.1111/head.70011.
    >> Share

  48. BLUMENFELD AM, Charleston L 4th, Kuruvilla D, Savage-Edwards B, et al
    OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trial.
    Headache. 2025 Dec 15. doi: 10.1111/head.70007.
    >> Share

  49. SCHWEDT TJ, Starling AJ, Ailani J, Hershey AD, et al
    Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society.
    Headache. 2025 Dec 10. doi: 10.1111/head.70023.
    >> Share

  50. TANG Y, Lu C, Zhou Y, Qian S, et al
    Treatment of abdominal migraine in an 8-year-old child with calcitonin gene-related peptide receptor antagonist: A case report.
    Headache. 2025 Dec 10. doi: 10.1111/head.70017.
    >> Share

  51. GUNASEKERA L, Cheng S, Foster E, Sivathamboo S, et al
    A retrospective audit of the real-world safety and effectiveness profile of eptinezumab for treatment-resistant chronic migraine in Australia.
    Headache. 2025 Dec 2. doi: 10.1111/head.70015.
    >> Share

  52. ROBBLEE J, Minen MT, Friedman BW, Cortel-LeBlanc MA, et al
    2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
    Headache. 2025 Dec 1. doi: 10.1111/head.70016.
    >> Share

    November 2025
  53. MUNOZ-VENDRELL A, Campoy-Diaz S, Diaz-Corta P, Termens L, et al
    False nonresponders to anti-calcitonin gene-related peptide monoclonal antibodies: A real-world analysis beyond migraine frequency reduction.
    Headache. 2025 Nov 28. doi: 10.1111/head.70012.
    >> Share

  54. ZHAO SJ, Wang TT, Zhang Q, Akerman S, et al
    The role of stress in the comorbidity of migraine and other chronic primary pain.
    Headache. 2025 Nov 26. doi: 10.1111/head.70004.
    >> Share

  55. LYSK S, Pach D, Tissen-Diabate T, Scholler S, et al
    Engagement and predictors of use of a smartphone app for migraine self-management: A secondary analysis of the EMMA trial.
    Headache. 2025 Nov 25. doi: 10.1111/head.70009.
    >> Share

  56. EL AHDAB J, Vilardo M, Ong B, Thompson NR, et al
    The effect of vestibular rehabilitation in the management of vestibular migraine in adults: A systematic review and meta-analysis.
    Headache. 2025 Nov 25. doi: 10.1111/head.70002.
    >> Share

  57. GAUL C, Ferreira S, Johansen T
    Partial rebreathing is not effective for early treatment of migraine with aura attacks: Results of a double-blind, randomized, controlled trial (PAREMA1).
    Headache. 2025 Nov 21. doi: 10.1111/head.15090.
    >> Share

  58. FERNANDEZ-BRAVO-RODRIGO J, Pascual-Morena C, Saz-Lara A, Martinez-Garcia I, et al
    Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis.
    Headache. 2025 Nov 17. doi: 10.1111/head.70003.
    >> Share

  59. KITAMURA S, Matsumori Y, Yamamoto T, Ishikawa T, et al
    Plain Language Summary Publication: Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.
    Headache. 2025 Nov 17. doi: 10.1111/head.15095.
    >> Share

  60. CHAUDHRY BA, Christensen RH, Ashina H, Al-Khazali HM, et al
    No differences in subcortical volume between people with and without migraine: A REFORM study.
    Headache. 2025 Nov 14. doi: 10.1111/head.70001.
    >> Share

  61. DE OLIVEIRA AB, Santos IS, Peres MFP, Conforto AB, et al
    Sex-specific differences in the relationship between AHA Life's Essential 8 factors and migraine disorders: A cross-sectional evaluation in ELSA-Brasil study.
    Headache. 2025 Nov 13. doi: 10.1111/head.15089.
    >> Share

  62. SZABO E, Gelfand AA
    Virtual issue: Real-world studies in migraine.
    Headache. 2025 Nov 6. doi: 10.1111/head.15088.
    >> Share

  63. VILLARUZ RH, Kuziek J, Sjonnesen K, Craddock L, et al
    Chinook winds and migraine attack onset in children and adolescents: A prospective longitudinal clinical cohort study.
    Headache. 2025 Nov 5. doi: 10.1111/head.15093.
    >> Share

  64. AILANI J, Charleston L 4th, Strom S, Albrecht D, et al
    Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study.
    Headache. 2025 Nov 4. doi: 10.1111/head.15086.
    >> Share

  65. WIELAND S, Emborg MS, de Wolff MG, Damm P, et al
    Use of antimigraine medication before pregnancy and in the first trimester: A cross-sectional study.
    Headache. 2025;65:1704-1715.
    >> Share

  66. GARELJA ML, Rees TA, Hay DL
    Calcitonin gene-related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme-linked immunosorbent assays.
    Headache. 2025;65:1744-1753.
    >> Share

    October 2025
  67. MORENO-AJONA D
    Persistent postural-perceptual dizziness versus vestibular migraine: A narrative review.
    Headache. 2025 Oct 28. doi: 10.1111/head.15078.
    >> Share

  68. NIU H, Robblee J
    Migraine in disguise: How over-the-counter medication labeling perpetuates the "sinus headache" myth.
    Headache. 2025 Oct 28. doi: 10.1111/head.15092.
    >> Share

  69. KARSAN N, Vandenbussche N, Jenia-Wilcha R, Amarasena P, et al
    Evaluating associations of migraine-related vertigo.
    Headache. 2025 Oct 26. doi: 10.1111/head.15038.
    >> Share

  70. WOLDEAMANUEL YW
    Editorial: Rethink your exercise for precision migraine management.
    Headache. 2025 Oct 26. doi: 10.1111/head.15077.
    >> Share

  71. LIM CN, Mo G, Bhardwaj R, Comisar CM, et al
    A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged >/=6 to <12 years) with a history of migraine.
    Headache. 2025 Oct 24. doi: 10.1111/head.15074.
    >> Share

  72. BAR M, Peles I, Ifergane G, Tsumi E, et al
    The association between migraine and glaucoma diseases: A retrospective cohort study.
    Headache. 2025 Oct 24. doi: 10.1111/head.15079.
    >> Share

  73. REDUCHA PV, Nielsen LKS, Jensen MN, Edvinsson JCA, et al
    TRPM3 activation causes CGRP release in trigeminal neurons: Implications for migraine mechanisms.
    Headache. 2025 Oct 24. doi: 10.1111/head.15082.
    >> Share

  74. OLIVEIRA DA SILVA R, Mendes Filho FSM, Pedrosa JGG, Pascual GS, et al
    Efficacy and tolerability of erenumab for chronic migraine in association with medication overuse: A systematic review and meta-analysis.
    Headache. 2025 Oct 22. doi: 10.1111/head.15068.
    >> Share

  75. QAISER S, Shady K
    Serum magnesium levels in children and adolescents with migraine: A prospective observational study.
    Headache. 2025 Oct 16. doi: 10.1111/head.15081.
    >> Share

  76. NAHAS SJ, Birlea M, Stark-Inbar A, Shmuely S, et al
    Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon.
    Headache. 2025 Oct 16. doi: 10.1111/head.15069.
    >> Share

  77. GRODZKA O, Boronczyk M, Zdunska A, Wegrzynek-Gallina J, et al
    Migraine and patent foramen ovale: correlation, coexistence, dependence. A narrative review.
    Headache. 2025 Oct 15. doi: 10.1111/head.15067.
    >> Share

  78. PERIS-SUBIZA J, Obach V, Guisado-Alonso D, Velasco Juanes F, et al
    Effectiveness and tolerability of galcanezumab for migraine prevention in patients >/=65 years: A real-life multicenter study.
    Headache. 2025 Oct 14. doi: 10.1111/head.15064.
    >> Share

  79. OGREZEANU DC, Nunez-Cortes R, Salazar-Mendez J, Cuyul-Vasquez I, et al
    How much aerobic exercise is needed to reduce migraine? A dose-response meta-analysis of pain intensity and frequency.
    Headache. 2025 Oct 14. doi: 10.1111/head.15070.
    >> Share

  80. PAIVA DA SILVA LIMA G, Rao R, Szabo G, Szklener S, et al
    Comprehensive assessment of erenumab efficacy in participants with high-frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study.
    Headache. 2025 Oct 14. doi: 10.1111/head.15071.
    >> Share

  81. WELLS RE, Floyd J, O'Brien H, Tamol N, et al
    Building a national headache medicine research network: The BE WELL with Migraine Champion Providers Network.
    Headache. 2025 Oct 9. doi: 10.1111/head.15065.
    >> Share

  82. NEWMAN LC, Lay C, Lipton RB, Ailani J, et al
    Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper.
    Headache. 2025 Oct 3. doi: 10.1111/head.15062.
    >> Share

    September 2025
  83. LIPTON RB, Lainez MJA, Ahmed Z, Vallarino C, et al
    Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study.
    Headache. 2025 Sep 29. doi: 10.1111/head.15045.
    >> Share

  84. LA N, Rattanapitoon SK, Rattanapitoon NK
    Cardiovascular risk considerations in triptan therapy for migraine: Reflections on the study by Peles et al.
    Headache. 2025 Sep 22. doi: 10.1111/head.15063.
    >> Share

  85. LEE KH, Liang CS, Yeh PK, Tsai CK, et al
    Insomnia severity in migraine: The role of headache frequency, aura status, and comorbidities-A cross-sectional study.
    Headache. 2025 Sep 19. doi: 10.1111/head.15055.
    >> Share

  86. O'HARE L, Hibbard PB, Wilkins AJ
    Evidence for increased background neural noise in migraine with aura: Hyperactive but not hyperresponsive.
    Headache. 2025 Sep 16. doi: 10.1111/head.15046.
    >> Share

  87. GOMEZ-DABO L, Gallardo VJ, Campos-Fernandez D, Rodrigo-Gisbert M, et al
    Persistent headache after aneurysmal subarachnoid hemorrhage: Prevalence, characteristics, and migraine history as a prognostic factor.
    Headache. 2025 Sep 15. doi: 10.1111/head.15052.
    >> Share

  88. CHARLES AC, Tepper SJ, Ailani J
    State of the art in the management of migraine-A response to the American College of Physicians migraine preventive treatment guideline.
    Headache. 2025 Sep 11. doi: 10.1111/head.15051.
    >> Share

  89. DE DHAEM OB, Verhaak A, Fajardo M, Grosberg B, et al
    Migraine in the workplace: Work productivity impact in a large US-based healthcare system using a cross-sectional employee survey.
    Headache. 2025 Sep 8. doi: 10.1111/head.15053.
    >> Share


  90. Correction to "Smartphone-delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial".
    Headache. 2025 Sep 3. doi: 10.1111/head.14939.
    >> Share

  91. ESPANIOLI A, van den Hoogen NJ, Kuziek J, Sjonnesen K, et al
    Exploring the relationship between pain catastrophizing and migraine in youth: A longitudinal clinical cohort study.
    Headache. 2025 Sep 1. doi: 10.1111/head.15039.
    >> Share

  92. LIPTON RB, Stokes J, Evans CJ, Hribal E, et al
    Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing.
    Headache. 2025 Sep 1. doi: 10.1111/head.15024.
    >> Share

  93. EZZATI A, Fanning KM, Teichrow D, Urani A, et al
    Headache Assessment via Digital Platform in United States: Baseline study characteristics, diagnosis, and treatment patterns.
    Headache. 2025;65:1428-1438.
    >> Share

    August 2025
  94. YOO A, Keenan B, Vgontzas A, Mittleman MA, et al
    Waning light, waxing pain: The lunar cycle's association with migraine headache occurrence.
    Headache. 2025 Aug 28. doi: 10.1111/head.15035.
    >> Share

  95. FISHBEIN JN, Schuster NM, Anders A, Portera AM, et al
    Pain Reprocessing Therapy for migraine: A case series.
    Headache. 2025 Aug 27. doi: 10.1111/head.15043.
    >> Share

  96. UNIYAL R, Garg RK, Verma R, Paliwal VK, et al
    Author response to comments on our article "Impact of perilesional edema on severity of migraine in patients with calcified neurocysticercosis: A prospective evaluation".
    Headache. 2025 Aug 26. doi: 10.1111/head.15029.
    >> Share

  97. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor regarding "Impact of perilesional edema on severity of migraine in patients with calcified neurocysticercosis: A prospective evaluation".
    Headache. 2025 Aug 26. doi: 10.1111/head.15036.
    >> Share

  98. YE S, Gao Y, Lin Y, Wang J, et al
    Ambient nitrogen dioxide, temperature exposure, and migraine incidence: A large prospective cohort study.
    Headache. 2025 Aug 26. doi: 10.1111/head.15037.
    >> Share

  99. LIANG J, Yang L, Yang Q, Zhang Y, et al
    Lessons from the coronavirus disease 2019 pandemic: Investigating the bidirectional relationship between coronavirus disease 2019 and migraine based on the MECH-HK cohort study.
    Headache. 2025 Aug 22. doi: 10.1111/head.15040.
    >> Share

  100. ORNELLO R, Salfi F, Vittorini MG, Innocenzi A, et al
    The potential role of sleep quality in the relationship between glymphatic function and migraine frequency: Insights from a cross-sectional study.
    Headache. 2025 Aug 19. doi: 10.1111/head.15019.
    >> Share

  101. GETZ M, Charleston L 4th, Armand CE, Willis AW, et al
    Plain Language Summary Publication: Perceived discrimination and migraine-specific quality of life: A cross-sectional survey study in a Black/African American sample.
    Headache. 2025 Aug 8. doi: 10.1111/head.15028.
    >> Share

  102. YANG F, Tian X, Xu Y, Yang S, et al
    A machine learning-driven transcriptomic study reveals the key role of Romo1 in reversing central sensitization through stellate ganglion block in migraine: An interventional study based on a recurrent migraine rat model.
    Headache. 2025 Aug 1. doi: 10.1111/head.14997.
    >> Share

    July 2025
  103. XIE S, Huo Y, Geng X, Hu L, et al
    Exploring the alterations in microstate dynamics during the migraine cycle and detecting pre-ictal phases.
    Headache. 2025 Jul 31. doi: 10.1111/head.15031.
    >> Share

  104. MANGANO GD, Antona V, Santangelo G, Di Pasquale G, et al
    A novel de novo AP2M1 variant in a patient with attention-deficit/hyperactivity disorder, oppositional defiant disorder, and unexpected hemiplegic migraine.
    Headache. 2025 Jul 28. doi: 10.1111/head.15017.
    >> Share

  105. RAQUIN M, Mrad Y, Zkim MA, Dallel R, et al
    Sex influences the progression of cephalic mechanical and light hypersensitivities in a mouse model of chronic migraine.
    Headache. 2025 Jul 25. doi: 10.1111/head.15015.
    >> Share

  106. VILA-PUEYO M, Goadsby PJ, Johnson KW, Holland PR, et al
    Galcanezumab reduces trigeminal nociception and is effective in preclinical models of migraine and trigeminal autonomic cephalalgias.
    Headache. 2025 Jul 21. doi: 10.1111/head.15006.
    >> Share

  107. DEMIRSOY I, Lipton RB, Ezzati A
    Real-world barriers to health care utilization among people living with migraine: Insights from the All of Us Research Program.
    Headache. 2025 Jul 15. doi: 10.1111/head.15007.
    >> Share

  108. FREIMARK G, Strauss S, Overeem LH, Fitzek MP, et al
    Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case-control study.
    Headache. 2025 Jul 15. doi: 10.1111/head.15021.
    >> Share

  109. ROSEN N, Jenkins A, Hygge Blakeman K, Dai F, et al
    Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States.
    Headache. 2025 Jul 12. doi: 10.1111/head.15004.
    >> Share

  110. SMIRNOFF L, Moskatel L, Shaw B, He Z, et al
    A retrospective cohort study to evaluate the effectiveness and safety profile of occipital nerve blocks in the treatment of migraine during pregnancy.
    Headache. 2025 Jul 7. doi: 10.1111/head.15001.
    >> Share

  111. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo S
    Letter to the Editor regarding "Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine".
    Headache. 2025;65:1060-1061.
    >> Share

  112. DE DIOS A, Pages-Puigdemont N, Ojeda S, Riera P, et al
    Response to the Letter to the Editor regarding "Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine".
    Headache. 2025;65:1062-1063.
    >> Share

  113. TASMA Z, Siow A, Harris PWR, Brimble MA, et al
    Development and pharmacological characterization of novel multi- calcitonin gene-related peptide and pituitary adenylate cyclase-activating peptide receptor antagonists.
    Headache. 2025;65:1064-1079.
    >> Share

    June 2025
  114. TERWINDT G, Ailani J, Cirillo J, Abraham L, et al
    Underdiagnosis and impact of menstrual migraine in real-world clinical practice: A real-world survey.
    Headache. 2025 Jun 30. doi: 10.1111/head.14996.
    >> Share

  115. IKEDA K, Matsumori Y, Kudo M, Ishikawa T, et al
    Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial.
    Headache. 2025 Jun 30. doi: 10.1111/head.14994.
    >> Share

  116. KUDROW D, Croop RS, Thiry A, Lipton RB, et al
    A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.
    Headache. 2025 Jun 30. doi: 10.1111/head.15002.
    >> Share

  117. MURPHY C, Ladak A, Szperka CL, De Prado BM, et al
    Response to: Reassessing pediatric migraine disability: Toward an updated assessment tool in the era of novel therapeutics.
    Headache. 2025 Jun 24. doi: 10.1111/head.14998.
    >> Share

  118. TAVASOLI AR, Hastriter EV, Little RD, Karnik KT, et al
    Reassessing pediatric migraine disability: Toward an updated assessment tool in the era of novel therapeutics.
    Headache. 2025 Jun 24. doi: 10.1111/head.14969.
    >> Share

  119. LIPTON RB, Gandhi P, Myers K, Bussberg C, et al
    Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete-choice experiment.
    Headache. 2025 Jun 24. doi: 10.1111/head.14974.
    >> Share

  120. PELES I, Shneyour RS, Levanon E, Steen YM, et al
    Cardiovascular risk and triptan usage among patients with migraine.
    Headache. 2025 Jun 22. doi: 10.1111/head.14968.
    >> Share

  121. KITAMURA S, Matsumori Y, Yamamoto T, Ishikawa T, et al
    Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.
    Headache. 2025 Jun 20. doi: 10.1111/head.14995.
    >> Share

  122. AHMAD SR, Levin M
    Prevalence of adverse childhood experiences in the refractory chronic migraine population compared to non-refractory chronic and episodic migraine.
    Headache. 2025 Jun 20. doi: 10.1111/head.14986.
    >> Share

  123. MONTEITH TS, Lazaridou A, Bernstein C
    Combination behavioral and pharmacological interventions through telehealth platforms: Opportunities for increasing access and optimizing migraine outcomes.
    Headache. 2025 Jun 19. doi: 10.1111/head.14993.
    >> Share

  124. BIRINGER RG
    Regulation of Na(+), K(+)-ATPase by cardiotonic steroids: Participation in the sodium theory for migraine.
    Headache. 2025 Jun 18. doi: 10.1111/head.14980.
    >> Share

  125. FOX J, Gaul C, Kuhlencord M, Peperkorn N, et al
    Identifying cognitive-affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions.
    Headache. 2025 Jun 17. doi: 10.1111/head.14988.
    >> Share

  126. BRACA S, Russo CV, Stornaiuolo A, Cretella G, et al
    Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study.
    Headache. 2025 Jun 17. doi: 10.1111/head.14991.
    >> Share

  127. LIAO CC, Lee CI, Huang YC, Liao KR, et al
    Causal associations between genetically predicted placental weight and migraine.
    Headache. 2025 Jun 11. doi: 10.1111/head.14977.
    >> Share

  128. COHEN F, Brooks CV, Sun D, Buse DC, et al
    What a long strange trip it's been: Reflections on serial snapshots of migraine prevalence and burden in the United States.
    Headache. 2025 Jun 5. doi: 10.1111/head.14984.
    >> Share

  129. GETZ M, Charleston L 4th, Armand CE, Willis AW, et al
    Perceived discrimination and migraine-specific quality of life: A cross-sectional survey study in a Black/African American sample.
    Headache. 2025 Jun 2. doi: 10.1111/head.14970.
    >> Share

  130. ORAK SA, Polat M, Pak M, Cerci Kubur C, et al
    Can serum neuropeptide levels help diagnose pediatric migraine? A prospective case-control study.
    Headache. 2025 Jun 2. doi: 10.1111/head.14981.
    >> Share

  131. GOLDSTEIN H, Rau LM, Humberg C, Bachhausen V, et al
    Efficacy of an educational website on headaches in schoolchildren: A cluster-randomized controlled trial.
    Headache. 2025;65:961-972.
    >> Share

    May 2025
  132. HERSHEY AD, Areberg J, Boserup LP, Lindsten A, et al
    Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine.
    Headache. 2025 May 30. doi: 10.1111/head.14959.
    >> Share

  133. NIKITINA V, Santi Laurini G, Montanaro N, Motola D, et al
    Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab.
    Headache. 2025 May 29. doi: 10.1111/head.14962.
    >> Share

  134. SEBROW L, Lipton RB, Metts CL, Mattis PJ, et al
    Cognition during ictal and interictal migraine phases: A pilot study using ecological momentary assessment.
    Headache. 2025 May 20. doi: 10.1111/head.14964.
    >> Share

  135. YOUSAF MIK, Hussey FD, Pavitt S, Irwin S, et al
    Memantine as a migraine prophylactic agent in adolescents: A retrospective analysis.
    Headache. 2025 May 20. doi: 10.1111/head.14979.
    >> Share

  136. JENSEN MKN, O'Connell ME, Mickleborough MJS
    Perceptions of health, cognition, and pain among middle-aged and older adults with migraine: A population-based cross-sectional study examining findings from the Canadian Longitudinal Study on Aging.
    Headache. 2025 May 20. doi: 10.1111/head.14953.
    >> Share

  137. BERMAN G, Mullin K, Smith T, Mosher L, et al
    Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open-label study.
    Headache. 2025 May 20. doi: 10.1111/head.14954.
    >> Share

  138. FERRAO MALHEIRO S, Dourado Sotero F, Pereira MB, Nunes Vicente B, et al
    Validation of a Portuguese version of the four-item Migraine Interictal Burden Scale.
    Headache. 2025 May 20. doi: 10.1111/head.14958.
    >> Share

  139. MEYDANAL YE, Senisik S, Sirin H
    The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study.
    Headache. 2025 May 20. doi: 10.1111/head.14951.
    >> Share

  140. KUCZYNSKI AM, Kingston WS
    Genetic migraine disorders and the response to calcitonin gene-related peptide antagonist treatment.
    Headache. 2025 May 8. doi: 10.1111/head.14942.
    >> Share

  141. PLANCHUELO-GOMEZ A, Martin-Martin C, Guerrero AL, Garcia-Azorin D, et al
    Long-term evolution of white and gray matter structural properties in migraine.
    Headache. 2025 May 8. doi: 10.1111/head.14949.
    >> Share

  142. TURKEL NN, Vuralli D, Bolay Belen H, Kuruoglu A, et al
    The association of migraine and autistic traits effects on anxiety, depression, and headache-related disability.
    Headache. 2025 May 5. doi: 10.1111/head.14945.
    >> Share

  143. DENG MG, Zhou X, Liu F, Wang K, et al
    Plain Language Summary Publication: Investigating the causal and genetic relationship between migraine and Parkinson's disease.
    Headache. 2025 May 5. doi: 10.1111/head.14947.
    >> Share

    April 2025
  144. GANTENBEIN AR, Kamm CP, Schankin CJ, Zecca C, et al
    Swiss Quality of Life and Health Care Impact Assessment in a Real-World Erenumab-Treated Migraine Population: Results over 2 years.
    Headache. 2025 Apr 30. doi: 10.1111/head.14943.
    >> Share

  145. HOUGAARD A
    Time to reconsider the association between migraine and white matter hyperintensities?
    Headache. 2025 Apr 16. doi: 10.1111/head.14940.
    >> Share

  146. SHIRANE R, Cohen F
    Counting the cost: How migraine shapes lives and economies.
    Headache. 2025 Apr 11. doi: 10.1111/head.14941.
    >> Share

  147. NIU PP, Zhang R, Zhang C, Li S, et al
    Association between migraine and cerebral white matter hyperintensities in middle-aged and older individuals: A cross-sectional study using the UK Biobank cohort.
    Headache. 2025 Apr 11. doi: 10.1111/head.14936.
    >> Share

  148. REIDY BL, Powers SW, King CD, Kabbouche M, et al
    Youth with high-frequency headaches due to migraine are more vulnerable to non-cephalic pain complaints.
    Headache. 2025;65:655-657.
    >> Share

  149. DE OLIVEIRA AB, Peres MFP, Mercante JPP, Brunoni AR, et al
    Associations of comorbid headache disorders and depression with leisure-time physical activity among 14,088 adults in The Brazilian Longitudinal Study of Adult Health.
    Headache. 2025;65:643-654.
    >> Share

    March 2025
  150. LEWIS JC, Orlova Y, Tietjen GE, Chiang CC, et al
    Migraine and spontaneous coronary artery dissection: A retrospective case-control study.
    Headache. 2025 Mar 28. doi: 10.1111/head.14935.
    >> Share

  151. RIMMELE F, Teuber J, Muller B, Giesen S, et al
    Afterimage duration differs for migraine with or without aura.
    Headache. 2025 Mar 28. doi: 10.1111/head.14934.
    >> Share

  152. LOPEZ-BRAVO A, Minguez-Olaondo A, Nieves-Castellanos C, Ruibal-Salgado M, et al
    Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study.
    Headache. 2025 Mar 26. doi: 10.1111/head.14913.
    >> Share

  153. NAIK VV, Uniyal R, Garg RK, Verma R, et al
    Impact of perilesional edema on severity of migraine in patients with calcified neurocysticercosis: A prospective evaluation.
    Headache. 2025 Mar 24. doi: 10.1111/head.14929.
    >> Share

  154. VGONTZAS A, Mittleman MA, Castro-Diehl C, Isasi CR, et al
    Migraine and sleep apnea, insomnia, and sleep patterns in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
    Headache. 2025 Mar 19. doi: 10.1111/head.14926.
    >> Share

  155. CHARLES AC, Goadsby PJ
    The cortical spreading depression/migraine aura hypothesis - Finally some definitive evidence.
    Headache. 2025 Mar 19. doi: 10.1111/head.14932.
    >> Share

  156. BUSE DC, Muenzel EJ, Zagar AJ, Mehrabadi AS, et al
    Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study.
    Headache. 2025 Mar 14. doi: 10.1111/head.14925.
    >> Share

  157. MAKITA LM, de Kleimmann RF, de Oliveira RR, Neves HAF, et al
    Assessing blood pressure changes and hypertension-related outcomes in patients with migraine treated with erenumab: A systematic review and meta-analysis.
    Headache. 2025 Mar 14. doi: 10.1111/head.14921.
    >> Share

  158. SUAREZ-BARCENA PD, Parra-Perez AM, Martin-Lagos J, Gallego-Martinez A, et al
    Machine learning models and classification algorithms in the diagnosis of vestibular migraine: A systematic review and meta-analysis.
    Headache. 2025 Mar 13. doi: 10.1111/head.14924.
    >> Share

  159. MCLEOD GA, Josephson CB, Engbers JDT, Cooke LJ, et al
    Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura.
    Headache. 2025 Mar 8. doi: 10.1111/head.14907.
    >> Share

  160. OURO A, Castro-Mosquera M, Rodriguez-Arrizabalaga M, Debasa-Mouce M, et al
    Serum levels of autotaxin reveal its role as a novel biomarker of migraine.
    Headache. 2025 Mar 4. doi: 10.1111/head.14922.
    >> Share

  161. DODICK DW, Tepper SJ, Ailani J, Khodavirdi AC, et al
    Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort study.
    Headache. 2025 Mar 3. doi: 10.1111/head.14912.
    >> Share

  162. LIPTON RB, Kollins JA, Albrecht D
    Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea-A narrative review.
    Headache. 2025;65:527-535.
    >> Share

    February 2025
  163. DE SANTIS F, Foschi M, Romoli M, Mastrangelo V, et al
    Do antithrombotic drugs have a role in migraine prevention? A systematic review.
    Headache. 2025 Feb 24. doi: 10.1111/head.14917.
    >> Share

  164. TREADWELL JR, Tsou AY, Rouse B, Ivlev I, et al
    Behavioral interventions for migraine prevention: A systematic review and meta-analysis.
    Headache. 2025 Feb 19. doi: 10.1111/head.14914.
    >> Share

  165. JEONG E, Mogos MF, Chen Y
    Association of migraine treatments with reduced ischemic stroke risk: Evidence from two large-scale real-world data analyses.
    Headache. 2025 Feb 14. doi: 10.1111/head.14918.
    >> Share

  166. YEH JT, Wang YF, Tzeng YS, Chen SP, et al
    Exploring the impact of acute SARS-CoV-2 infection on headache pattern in patients with migraine: A novel Bayesian analysis.
    Headache. 2025 Feb 10. doi: 10.1111/head.14911.
    >> Share

  167. CHEN TY, Hsieh TY, Wang YH, Chang R, et al
    Association between obstructive sleep apnea and migraine: A United States population-based cohort study.
    Headache. 2025 Feb 10. doi: 10.1111/head.14904.
    >> Share

  168. SMIRNOFF L, Moskatel LS
    Dyspareunia and pelvic pain in women with chronic migraine: A retrospective, observational analysis.
    Headache. 2025 Feb 4. doi: 10.1111/head.14905.
    >> Share

  169. ROMOZZI M, Munafo A, Burgalassi A, De Cesaris F, et al
    Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review.
    Headache. 2025;65:342-352.
    >> Share

  170. MANGOLD KI, Katta T, Do V, Moore RD, et al
    White matter hyperintensities and headache in United States military veterans with mild traumatic brain injury.
    Headache. 2025;65:206-215.
    >> Share

    January 2025
  171. KUAN AS, Wang YF, Chen SP, Chuang YF, et al
    Sex differences in pain, suicidal ideation, and suicide attempts in patients with migraine.
    Headache. 2025 Jan 24. doi: 10.1111/head.14906.
    >> Share

  172. SENG EK, Muenzel EJ, Shapiro RE, Buse DC, et al
    Development of the Migraine-Related Stigma (MiRS) Questionnaire: Results of the OVERCOME (US) Study.
    Headache. 2025 Jan 22. doi: 10.1111/head.14886.
    >> Share

  173. SILVESTRI G, Roccatagliata L, Tazza F, Schiavi S, et al
    The "central vein sign" to differentiate multiple sclerosis from migraine.
    Headache. 2025 Jan 20. doi: 10.1111/head.14902.
    >> Share

  174. HARO M, Garate G, Hernandez JL, Olmos JM, et al
    Low serum 25-hydroxyvitamin D levels in migraine are not related to headache frequency: A case-control study in patients with high-frequency/chronic migraine.
    Headache. 2025 Jan 13. doi: 10.1111/head.14901.
    >> Share

  175. MINEN MT, Whetten C, Messier D, Mehta S, et al
    Headache diagnosis and treatment: A pilot knowledge and needs assessment among physical therapists.
    Headache. 2025;65:90-100.
    >> Share

  176. RIVA E, Kurtis MM, Valls A, Franch O, et al
    Beyond movement: Headache in patients with functional movement disorders.
    Headache. 2025;65:197-201.
    >> Share

    December 2024
  177. BLASZCZYK B, Waliszewska-Prosol M, Smardz J, Wieckiewicz M, et al
    Exploring the associations of sleep bruxism and obstructive sleep apnea with migraine among patients with temporomandibular disorder: A polysomnographic study.
    Headache. 2024 Dec 30. doi: 10.1111/head.14892.
    >> Share

  178. YAN L, Huang Y, Xie B, Liu Z, et al
    Association of periodontitis and periodontal parameters with migraine and mortality in people with migraine disease: A nationally representative observational study.
    Headache. 2024 Dec 30. doi: 10.1111/head.14893.
    >> Share

  179. OLSON PA, Powers SW
    Behavior and migraine virtual issue.
    Headache. 2024 Dec 30. doi: 10.1111/head.14896.
    >> Share

  180. SHARIFI A, Kouhi A, Steenerson KK, Sharon JD, et al
    Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI) : A narrative review.
    Headache. 2024 Dec 30. doi: 10.1111/head.14866.
    >> Share

  181. JAIMES A, Gomez A, Pajares O, Rodriguez-Vico J, et al
    Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study.
    Headache. 2024 Dec 27. doi: 10.1111/head.14865.
    >> Share

  182. SU TH, Wang JK, Kuo PH, Chang SH, et al
    The pathogenic role of calcitonin gene-related peptide and predictors of new-onset migraine and long-term outcomes after transcatheter atrial septal defect closure.
    Headache. 2024 Dec 11. doi: 10.1111/head.14885.
    >> Share

  183. DENG MG, Zhou X, Liu F, Wang K, et al
    Investigating the causal and genetic relationship between migraine and Parkinson's disease.
    Headache. 2024 Dec 10. doi: 10.1111/head.14881.
    >> Share

    November 2024
  184. HUSSEIN M, Hassan A, Nada MAF, Mohammed Z, et al
    Validity, reliability, and sensitivity to change of the Arabic version of the Migraine-Specific Quality-of-Life Questionnaire after prophylactic treatment.
    Headache. 2024 Nov 27. doi: 10.1111/head.14874.
    >> Share

  185. PANZA GA, Johnson MAL, Kuruvilla DE
    A post hoc analysis of migraine-associated symptoms from the phase 3 randomized, double-blind, sham-controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine (TEAM) study.
    Headache. 2024 Nov 27. doi: 10.1111/head.14860.
    >> Share

  186. LIPTON RB, Gendolla A, Abraham L, Jenkins A, et al
    Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review.
    Headache. 2024 Nov 27. doi: 10.1111/head.14854.
    >> Share

  187. AILANI J, Lipton RB, Blumenfeld AM, Mechtler L, et al
    Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.
    Headache. 2024 Nov 21. doi: 10.1111/head.14871.
    >> Share

  188. GOPALAKRISHNAN R, Malan NS, Mandava N, Dunn EJ, et al
    Magnetoencephalography studies in migraine and headache disorders: A systematic review.
    Headache. 2024 Nov 10. doi: 10.1111/head.14867.
    >> Share

  189. DAGHLAS I, Rist PM, Chasman DI
    Genetically proxied liability to migraine and risk of intracranial aneurysm and subarachnoid hemorrhage.
    Headache. 2024 Nov 7. doi: 10.1111/head.14851.
    >> Share

  190. BERTZ RJ, Collins JL, Madonia J, Bhardwaj R, et al
    Comparative bioavailability of single-dose zavegepant during and between migraine attacks: A phase 1, randomized, open-label, fixed-sequence, two-period study.
    Headache. 2024 Nov 7. doi: 10.1111/head.14856.
    >> Share

  191. GRYGLAS-DWORAK A, Schim J, Ettrup A, Boserup LP, et al
    Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.
    Headache. 2024 Nov 5. doi: 10.1111/head.14862.
    >> Share

  192. SHEWALE AR, Poh W, Reed ML, Liu J, et al
    Ubrogepant users' real-world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study.
    Headache. 2024;64:1244-1252.
    >> Share

  193. CASCELLA RH, Anderson CC, Perez EJ
    The impact of updates in headache quality measures on adherence to best practices in a neurology resident clinic: A quality improvement study.
    Headache. 2024;64:1329-1335.
    >> Share

    October 2024
  194. PATTERSON GENTILE C, Szperka CL, Hershey AD
    Cluster Analysis of Migraine-associated Symptoms (CAMS) in youth: A retrospective cross-sectional multicenter study.
    Headache. 2024 Oct 27. doi: 10.1111/head.14859.
    >> Share

  195. PATTERSON GENTILE C, Hershey AD, Szperka CL
    A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross-sectional headache registry study in youth.
    Headache. 2024 Oct 27. doi: 10.1111/head.14858.
    >> Share

  196. COHEN F, Brooks CV, Sun D, Buse DC, et al
    Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findings.
    Headache. 2024 Oct 23. doi: 10.1111/head.14864.
    >> Share

  197. TAVASOLI AR, Rastogi RG, Hastriter EV
    Rising migraine incidence in adolescents despite stable prevalence in the US: A call for further investigation.
    Headache. 2024 Oct 19. doi: 10.1111/head.14844.
    >> Share

  198. SENG EK, Hill J, Reeder AK, Visvanathan P, et al
    Feasibility, acceptability, and fidelity of remote-delivered abbreviated mindfulness-based cognitive therapy interventions for patients with migraine and depressive symptoms.
    Headache. 2024 Oct 14. doi: 10.1111/head.14857.
    >> Share

  199. RUIZ-TAGLE A, Caetano G, Fouto A, Esteves I, et al
    Preserved working memory performance along with subcortical modulation during peri-ictal phases in spontaneous migraine attacks.
    Headache. 2024 Oct 13. doi: 10.1111/head.14850.
    >> Share

  200. KIRKLAND S, Meyer J, Visser L, Campbell S, et al
    The effectiveness of parenteral agents to mitigate relapses after severe acute migraine headache presentations: A systematic review and network analysis.
    Headache. 2024 Oct 4. doi: 10.1111/head.14841.
    >> Share

  201. BHARDWAJ R, Donohue MK, Madonia J, Matschke K, et al
    Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo-controlled study in healthy adults.
    Headache. 2024 Oct 4. doi: 10.1111/head.14853.
    >> Share

  202. TUMMOSZEIT IZ, Olofsson IA, Chalmer MA, Henriksen AP, et al
    No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study.
    Headache. 2024 Oct 1. doi: 10.1111/head.14784.
    >> Share

    September 2024
  203. SOTTANI C, Di Lazzaro G, Calabresi P, Pomponi MG, et al
    Efficacy of galcanezumab in proline-rich transmembrane protein 2 (PRRT2)-associated familial hemiplegic migraine: A case series.
    Headache. 2024 Sep 30. doi: 10.1111/head.14840.
    >> Share

  204. SHARON JD, Krauter R, Chae R, Gardi A, et al
    A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study.
    Headache. 2024 Sep 30. doi: 10.1111/head.14835.
    >> Share

  205. PEASAH SK, Soh YH, Huang Y, Nguyen J, et al
    Patient reported outcomes and the real-world use of calcitonin gene-related peptide medications in migraine.
    Headache. 2024 Sep 30. doi: 10.1111/head.14843.
    >> Share

  206. ORR SL, Kuziek J, Ali S, Anderson E, et al
    Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double-dummy pilot trial.
    Headache. 2024 Sep 17. doi: 10.1111/head.14838.
    >> Share

  207. SOTERO FD, Nobre J, Vicente BN, Martins IP, et al
    Predictors of migraine interictal burden: The hidden role of subjective memory complaints.
    Headache. 2024 Sep 13. doi: 10.1111/head.14819.
    >> Share

  208. KANG S, Eun Y, Han K, Jung J, et al
    Heightened migraine risk in patients with rheumatoid arthritis: A national retrospective cohort study.
    Headache. 2024 Sep 13. doi: 10.1111/head.14832.
    >> Share

  209. DE DIOS A, Pages-Puigdemont N, Ojeda S, Riera P, et al
    Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine.
    Headache. 2024 Sep 13. doi: 10.1111/head.14827.
    >> Share

  210. MULTANI JK, Urman R, Park AS, Gill K, et al
    Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study.
    Headache. 2024 Sep 9. doi: 10.1111/head.14820.
    >> Share

  211. AILANI J, Gandhi P, Lalla A, Halker Singh R, et al
    Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine.
    Headache. 2024 Sep 9. doi: 10.1111/head.14824.
    >> Share

  212. MCGINLEY JS, Mangrum R, Gerstein MT, McCarrier KP, et al
    Symptoms across the phases of the migraine cycle from the patient's perspective: Results of the MiCOAS qualitative study.
    Headache. 2024 Sep 2. doi: 10.1111/head.14817.
    >> Share

  213. TATSUMOTO M, Ishida M, Iba K, Kim BK, et al
    Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial.
    Headache. 2024 Sep 2. doi: 10.1111/head.14810.
    >> Share

  214. MOHAMMADNEZHAD G, Assarzadegan F, Koosha M, Esmaily H, et al
    Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial.
    Headache. 2024 Sep 2. doi: 10.1111/head.14808.
    >> Share

  215. MARTIN EG, Kuziek J, Rasiah J, Orr SL, et al
    Evaluating patient and family preferences for acute and preventive pediatric headache treatment.
    Headache. 2024;64:950-966.
    >> Share

    August 2024
  216. SMITH DC, Zhang J, Jayasuriya S, Berisha V, et al
    The impact of headache intensity on speech in participants with migraine and acute post-traumatic headache.
    Headache. 2024 Aug 28. doi: 10.1111/head.14809.
    >> Share

  217. FUGLSANG CH, Pedersen L, Schmidt M, Vandenbroucke JP, et al
    The combined impact of migraine and gestational diabetes on long-term risk of premature myocardial infarction and stroke: A population-based cohort study.
    Headache. 2024 Aug 28. doi: 10.1111/head.14821.
    >> Share

  218. KIM JR, Park TJ, Agapova M, Blumenfeld A, et al
    Healthcare resource use and costs associated with the misdiagnosis of migraine.
    Headache. 2024 Aug 28. doi: 10.1111/head.14822.
    >> Share

  219. HERBERT MS, Merritt VC, Afari N, Gasperi M, et al
    Cognitive symptoms in veterans with migraine or traumatic brain injury: A Million Veteran Program study.
    Headache. 2024 Aug 28. doi: 10.1111/head.14815.
    >> Share

  220. DENNEY DE, Lee AA, Landy SH, Smitherman TA, et al
    Plain language summary publication: Headache-related disability as a function of migraine aura: A daily diary study.
    Headache. 2024 Aug 23. doi: 10.1111/head.14811.
    >> Share

  221. CHIANG CC, Schwedt TJ, Dumkrieger G, Wang L, et al
    Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features.
    Headache. 2024 Aug 23. doi: 10.1111/head.14806.
    >> Share

  222. SHARMA TL, Lucas S, Barber J, Hoffman JM, et al
    Pilot study evaluating treatment with sumatriptan for moderate to severe post-traumatic headache: A phase 2 open-label study.
    Headache. 2024 Aug 13. doi: 10.1111/head.14807.
    >> Share

  223. LINDSAY R, Kalifa A, Kuziek J, Kabbouche M, et al
    The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta-analysis.
    Headache. 2024 Aug 11. doi: 10.1111/head.14798.
    >> Share

  224. DENNEY DE, Lee AA, Landy SH, Smitherman TA, et al
    Headache-related disability as a function of migraine aura: A daily diary study.
    Headache. 2024 Aug 1. doi: 10.1111/head.14796.
    >> Share

  225. SUZUKI Y, Kiyosawa M, Wakakura M, Ishii K, et al
    Plain Language Summary Publication: Hyperactivity of the medial thalamus in patients with photophobia-associated migraine.
    Headache. 2024 Aug 1. doi: 10.1111/head.14792.
    >> Share

    July 2024
  226. DUMKRIEGER GM, Ishii R, Goadsby PJ
    Flexible modeling of headache frequency fluctuations in migraine with hidden Markov models.
    Headache. 2024 Jul 30. doi: 10.1111/head.14782.
    >> Share

  227. TRIVEDI M, Dumkrieger G, Chong CD, Leibovit-Reiben Z, et al
    A history of abuse is associated with more severe migraine- and pain-related disability: Results from the American Registry for Migraine Research.
    Headache. 2024 Jul 25. doi: 10.1111/head.14787.
    >> Share

  228. SUZUKI Y, Kiyosawa M, Wakakura M, Ishii K, et al
    Hyperactivity of the medial thalamus in patients with photophobia-associated migraine.
    Headache. 2024 Jul 18. doi: 10.1111/head.14785.
    >> Share

  229. BURNS KN, Zhao H, Master C, Langford D, et al
    Migraine epidemiology in collegiate student-athletes: Findings from the Concussion Assessment, Research, and Education (CARE) Consortium.
    Headache. 2024 Jul 18. doi: 10.1111/head.14799.
    >> Share

  230. OLOFSSON IA
    Migraine heritability and beyond: A scoping review of twin studies.
    Headache. 2024 Jul 18. doi: 10.1111/head.14789.
    >> Share

  231. CHARLESTON L 4TH
    Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Association: A pilot project.
    Headache. 2024 Jul 16. doi: 10.1111/head.14791.
    >> Share

  232. ORNELLO R, Baldini F, Onofri A, Rosignoli C, et al
    Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway-A real-world study.
    Headache. 2024 Jul 16. doi: 10.1111/head.14788.
    >> Share

  233. MATHARU M, Katsarava Z, Buse DC, Sommer K, et al
    Plain Language Summary Publication: Characterizing neck pain during headache among people with migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) cross-sectional study.
    Headache. 2024 Jul 16. doi: 10.1111/head.14786.
    >> Share

  234. BOUGIE JK, Krupsky K, Beusterien K, Ladouceur MP, et al
    Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment.
    Headache. 2024 Jul 9. doi: 10.1111/head.14781.
    >> Share

  235. LIPTON RB, Ailani J, Mullin K, Pavlovic JM, et al
    Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
    Headache. 2024 Jul 3. doi: 10.1111/head.14775.
    >> Share

  236. ROBBLEE J, Orlova YY, Ahn AH, Ali AS, et al
    Real-world approaches to outpatient treatment of status migrainosus: A survey study.
    Headache. 2024 Jul 3. doi: 10.1111/head.14769.
    >> Share

  237. SILBERSTEIN SD, Diener HC, Dodick DW, Sommer K, et al
    Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Headache. 2024;64:838-848.
    >> Share

  238. MATHARU M, Katsarava Z, Buse DC, Sommer K, et al
    Characterizing neck pain during headache among people with migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) cross-sectional study.
    Headache. 2024;64:750-763.
    >> Share

  239. ROBBLEE J, Zhao XR, Minen MT, Friedman BW, et al
    Plain Language Summary Publication: The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American headache society evidence assessment of parenteral pharmacotherapies.
    Headache. 2024;64:901-902.
    >> Share

  240. KLAN T, Brascher AK, Seng EK, Gaul C, et al
    German language adaptation of the Cogniphobia Scale for Headache Disorders (CS-HD) and development of a new short form (CS-HD-6).
    Headache. 2024;64:772-782.
    >> Share

    June 2024
  241. ORR SL
    Parental mental health and migraine in youth: An evolving story historically plagued with sparse and inadequate literature and mother-blaming.
    Headache. 2024 Jun 27. doi: 10.1111/head.14779.
    >> Share

  242. MARZOUK MA, Buse DC, Karvounides D, Powers SW, et al
    Not their fault: Mental health characteristics of parents with migraine and the migraine status of their children.
    Headache. 2024 Jun 27. doi: 10.1111/head.14773.
    >> Share

  243. VURAL S, Turksoy VA, Uzun Akgeyik A, Kusdogan M, et al
    Heavy metal and trace element alterations in patients during a migraine attack.
    Headache. 2024 Jun 27. doi: 10.1111/head.14748.
    >> Share

  244. VIVES-MESTRES M, Casanova A, Silberstein SD, Hershey AD, et al
    Clinical factors associated with day-to-day peak pain severity in individuals with chronic migraine: A cohort study using daily prospective diary data.
    Headache. 2024 Jun 27. doi: 10.1111/head.14745.
    >> Share

  245. BLUMENFELD A, Kudrow D, McAllister P, Boserup LP, et al
    Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache.
    Headache. 2024 Jun 24. doi: 10.1111/head.14767.
    >> Share

  246. PASCUAL-MATO M, Garate G, Gonzalez-Quintanilla V, Madera-Fernandez J, et al
    Differences in circulating alpha-calcitonin gene-related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study.
    Headache. 2024 Jun 24. doi: 10.1111/head.14768.
    >> Share

  247. CROPPER HC, Conway CM, Wyche W, Pradhan AA, et al
    Glial activation in pain and emotional processing regions in the nitroglycerin mouse model of chronic migraine.
    Headache. 2024 Jun 20. doi: 10.1111/head.14740.
    >> Share

  248. JOSHI S, Spargo A, Hoyt M, Panni T, et al
    A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
    Headache. 2024 Jun 19. doi: 10.1111/head.14741.
    >> Share

  249. NANDYALA A, Burch R, Halker Singh R
    Migraine in women.
    Headache. 2024 Jun 14. doi: 10.1111/head.14783.
    >> Share

  250. WELLS RE, O'Connell N, Minen MT
    Mechanisms for mindfulness in migraine: Does catastrophizing matter?
    Headache. 2024 Jun 6. doi: 10.1111/head.14730.
    >> Share

  251. CONTI M, Bovenzi R, Palmieri MG, Placidi F, et al
    Early effect of onabotulinumtoxinA on EEG-based functional connectivity in patients with chronic migraine: A pilot study.
    Headache. 2024 Jun 4. doi: 10.1111/head.14750.
    >> Share

  252. ROBBLEE J, Zhao XR, Minen MT, Friedman BW, et al
    The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
    Headache. 2024 Jun 3. doi: 10.1111/head.14744.
    >> Share

    May 2024
  253. DAFER RM, Tietjen GE, Rothrock JF, Vann RE, et al
    Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
    Headache. 2024 May 27. doi: 10.1111/head.14669.
    >> Share

  254. SU Y, Tay VQ, Singh S, Leary MC, et al
    A retrospective review of sex differences of white matter hyperintensities in brain MRI of patients with migraine.
    Headache. 2024 May 24. doi: 10.1111/head.14714.
    >> Share

  255. WANG SJ, Kim BK, Wang H, Zhou J, et al
    Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study.
    Headache. 2024 May 24. doi: 10.1111/head.14733.
    >> Share

  256. ZHAO YJ, Ong JJY, Sonu SK, Dang J, et al
    A real-world prospective observational study of eptinezumab in Asian patients with migraine.
    Headache. 2024 May 24. doi: 10.1111/head.14737.
    >> Share

  257. ASHINA S, Muenzel EJ, Nicholson RA, Zagar AJ, et al
    Machine learning identifies factors most associated with seeking medical care for migraine: Results of the OVERCOME (US) study.
    Headache. 2024 May 24. doi: 10.1111/head.14729.
    >> Share

  258. SHAO SC, Hentz J, Shank P, Leonard M, et al
    Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial.
    Headache. 2024 May 23. doi: 10.1111/head.14732.
    >> Share

  259. MAY A
    Beyond aura: Understanding migraine as a cycling pan-sensory threshold disease.
    Headache. 2024 May 23. doi: 10.1111/head.14736.
    >> Share

  260. BUSE DC, Sakai F, Matharu M, Reed ML, et al
    Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi-country results from the CaMEO-I study.
    Headache. 2024 May 5. doi: 10.1111/head.14721.
    >> Share

  261. ANDERSON CC, Iser CR, Hirte IL, Boddu S, et al
    Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
    Headache. 2024 May 3. doi: 10.1111/head.14725.
    >> Share

  262. COHEN F, Brooks CV, Sun D, Buse DC, et al
    Prevalence and burden of migraine in the United States: A systematic review.
    Headache. 2024 May 3. doi: 10.1111/head.14709.
    >> Share

  263. REDUCHA PV, Bomers JP, Edvinsson L, Haanes KA, et al
    The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model.
    Headache. 2024 May 3. doi: 10.1111/head.14726.
    >> Share

  264. INCE MS, Guzel I, Akgor MC, Bahcelioglu M, et al
    Virtual dynamic interaction games reveal impaired multisensory integration in women with migraine.
    Headache. 2024 May 1. doi: 10.1111/head.14720.
    >> Share

    April 2024
  265. XU D, Wu B
    Investigating the causal association between systemic lupus erythematosus and migraine using Mendelian randomization analysis.
    Headache. 2024 Apr 28. doi: 10.1111/head.14723.
    >> Share

  266. ZHU G, Wang M, Kong F
    Blood serum levels of PACAP and migraine onset: A systematic review and meta-analysis of observational studies.
    Headache. 2024 Apr 24. doi: 10.1111/head.14711.
    >> Share

  267. HUSSEIN M, Hassan A, Nada MAF, Mohammed Z, et al
    Reliability, validity, and responsiveness of the Arabic version of HIT-6 questionnaire in patients with migraine indicated for preventive therapy: A multi-center study.
    Headache. 2024 Apr 23. doi: 10.1111/head.14719.
    >> Share

  268. ERMAKOVA E, Shaidullova K, Gafurov O, Kabirova A, et al
    Implications of high homocysteine levels in migraine pain: An experimental study of the excitability of peripheral meningeal afferents in rats with hyperhomocysteinemia.
    Headache. 2024 Apr 22. doi: 10.1111/head.14710.
    >> Share

  269. VYAS MV, Lee N, Lay C
    Association between migraine and exclusive breastfeeding: A cross-sectional study.
    Headache. 2024 Apr 21. doi: 10.1111/head.14713.
    >> Share

  270. GELFAND AA
    Depression and anxiety are not associated with migraine outcomes in children and adolescents.
    Headache. 2024 Apr 18. doi: 10.1111/head.14700.
    >> Share

  271. ROBBLEE J, Hakim SM, Reynolds JM, Monteith TS, et al
    Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
    Headache. 2024 Apr 18. doi: 10.1111/head.14693.
    >> Share

  272. REINA-VARONA A, Madronero-Miguel B, Fierro-Marrero J, Paris-Alemany A, et al
    Efficacy of various exercise interventions for migraine treatment: A systematic review and network meta-analysis.
    Headache. 2024 Apr 10. doi: 10.1111/head.14696.
    >> Share

  273. RIZVI BA, Kuziek J, Cho LY, Ronksley PE, et al
    Anxiety and depressive symptoms and migraine-related outcomes in children and adolescents.
    Headache. 2024 Apr 6. doi: 10.1111/head.14701.
    >> Share

  274. KIRKLAND SW, Visser L, Meyer J, Junqueira DR, et al
    The effectiveness of parenteral agents for pain reduction in patients with migraine presenting to emergency settings: A systematic review and network analysis.
    Headache. 2024;64:424-447.
    >> Share

  275. SEEBADRI-WHITE C, Yuan H, Young WB, Arca KN, et al
    Advocacy Connection Team-Now educational program for headache fellows and patients/caregivers: Assessment of educational objectives.
    Headache. 2024;64:374-379.
    >> Share

    March 2024
  276. DODICK DW, Reed ML, Lee L, Balkaran BL, et al
    Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States.
    Headache. 2024 Mar 24. doi: 10.1111/head.14684.
    >> Share

  277. KRIKOVA I, Digre KB, Katz BJ, Seay MD, et al
    Migraine, idiopathic intracranial hypertension, and calcitonin gene-related peptide antibodies.
    Headache. 2024 Mar 13. doi: 10.1111/head.14686.
    >> Share

  278. CHARLES AC, Digre KB, Goadsby PJ, Robbins MS, et al
    Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
    Headache. 2024 Mar 11. doi: 10.1111/head.14692.
    >> Share

  279. SPROUSE BLUM AS, DaSilva LA, Greenberg MD, Nissenbaum AJ, et al
    Comparison of migraine with left- versus right-sided headache: A cross-sectional study.
    Headache. 2024 Mar 3. doi: 10.1111/head.14689.
    >> Share

  280. HOOGEVEEN ES, Pelzer N, Ghariq E, van Osch MJP, et al
    Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual-echo arterial spin labeling MRI study.
    Headache. 2024 Mar 2. doi: 10.1111/head.14680.
    >> Share

  281. GIBLER RC, Knestrick KE, Powers SW, Hershey AD, et al
    Preliminary prospective observational investigation of clinical outcomes among treatment-seeking youth with continuous headache.
    Headache. 2024;64:319-322.
    >> Share

  282. LIPTON RB, Albrecht D, Bermudez M, Hu J, et al
    A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
    Headache. 2024;64:266-275.
    >> Share

    February 2024
  283. SCUTELNIC A, Sutter NL, Beyeler M, Meinel TR, et al
    Characteristics of acute ischemic stroke and unusual aura in patients with migraine with aura.
    Headache. 2024 Feb 27. doi: 10.1111/head.14682.
    >> Share

  284. CHHABRA N, Mead-Harvey C, Dodoo CA, Iser C, et al
    Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience.
    Headache. 2024 Feb 27. doi: 10.1111/head.14679.
    >> Share


  285. Correction to: "Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial".
    Headache. 2024 Feb 26. doi: 10.1111/head.14691.
    >> Share

  286. ROSSIGNOL J, Ouimet T, Poras H, Dallel R, et al
    Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine.
    Headache. 2024 Feb 22. doi: 10.1111/head.14681.
    >> Share

  287. MITTLEMAN MR, Mostofsky E, Vgontzas A, Bertisch SM, et al
    Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study.
    Headache. 2024 Feb 6. doi: 10.1111/head.14673.
    >> Share

  288. VAN DEN HOEK TC, Verhagen IE, de Boer I, Terwindt GM, et al
    Substance use in a Dutch migraine cohort compared with the general population.
    Headache. 2024 Feb 1. doi: 10.1111/head.14663.
    >> Share

  289. LANGDON RL, DiSabella MT, Strelzik JA
    Screen time and pediatric headache: A scoping review of the literature.
    Headache. 2024;64:211-225.
    >> Share

  290. HAN C, Lim JY, Koike N, Kim SY, et al
    Regulation of headache response and transcriptomic network by the trigeminal ganglion clock.
    Headache. 2024;64:195-210.
    >> Share

  291. JICHA C, Pham K
    Neuromodulation for primary headache disorders: Advantages and challenges.
    Headache. 2024;64:226-228.
    >> Share

  292. PRADHAN SK, Gantenbein AR, Li Y, Shaban H, et al
    Daith piercing: Revisited from the perspective of auricular acupuncture systems. A narrative review.
    Headache. 2024;64:131-140.
    >> Share

    January 2024
  293. ZHANG P, Ventrapragada A, Shapiro RE, Do TP, et al
    Metaphorical use of "headache" and "migraine" in media: A longitudinal study of 1.3 million articles in major publications.
    Headache. 2024 Jan 18. doi: 10.1111/head.14661.
    >> Share

  294. VGONTZAS A
    Examining substance use patterns in adults with migraine: A changing landscape.
    Headache. 2024 Jan 18. doi: 10.1111/head.14660.
    >> Share

  295. MANGRUM R, Bryant AL, Gerstein MT, McCarrier KP, et al
    The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine.
    Headache. 2024 Jan 18. doi: 10.1111/head.14664.
    >> Share

  296. PATNIYOT I, Banerjee A, Nobleza K, Nguyen D, et al
    A retrospective analysis of the use of candesartan for migraine prevention in adolescents.
    Headache. 2024;64:96-97.
    >> Share

  297. DE OLIVEIRA FAA, Dourado-Filho MG, Sampaio Rocha-Filho PA
    Persistent headache attributed to past ischemic stroke: A prospective cohort study.
    Headache. 2024;64:48-54.
    >> Share

    December 2023
  298. BELTRAMONE M, Redon S, Donnet A
    Bone site fracture pain after subcutaneous sumatriptan injection: A report of two cases.
    Headache. 2023 Dec 29. doi: 10.1111/head.14662.
    >> Share

  299. RHUDY C, Schadler A, Huffmyer M, Porter L, et al
    Rural disparities in emergency department utilization for migraine care.
    Headache. 2023 Dec 12. doi: 10.1111/head.14659.
    >> Share

  300. CHASE BA, Semenov I, Rubin S, Meyers S, et al
    Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
    Headache. 2023 Dec 10. doi: 10.1111/head.14655.
    >> Share

    November 2023
  301. PODRAZA K, Bangera N, Feliz A, Charles A, et al
    Reduction in retinal microvascular perfusion during migraine attacks.
    Headache. 2023 Nov 30. doi: 10.1111/head.14654.
    >> Share

  302. MACGREGOR EA, Okonkwo R, Detke HC, Polavieja P, et al
    Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2.
    Headache. 2023 Nov 28. doi: 10.1111/head.14652.
    >> Share

  303. ASHINA M, Mitsikostas DD, Ramirez Campos V, Barash S, et al
    Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
    Headache. 2023 Nov 13. doi: 10.1111/head.14651.
    >> Share

  304. WU J, Yang P, Wu X, Yu X, et al
    Association between secondhand smoke exposure and severe headaches or migraine in never-smoking adults.
    Headache. 2023 Nov 8. doi: 10.1111/head.14640.
    >> Share

  305. SZPERKA CL, Witzman S, Ostapenko S, Farrar JT, et al
    Patient headache questionnaires can improve headache diagnosis and treatment in children.
    Headache. 2023;63:1359-1371.
    >> Share

  306. IACONANGELO CJ, Serrano D, Adams AM, Trugman JM, et al
    Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials.
    Headache. 2023;63:1412-1422.
    >> Share

  307. HYERACI G, Paoletti O, Iannone LF, Gini R, et al
    Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
    Headache. 2023;63:1391-1402.
    >> Share

  308. MERLI E, Rustici A, Gramegna LL, Di Donato M, et al
    Vessel-wall MRI in primary headaches: The role of neurogenic inflammation.
    Headache. 2023;63:1372-1379.
    >> Share

    October 2023
  309. MOSKATEL LS, Graber-Naidich A, He Z, Zhang N, et al
    The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
    Headache. 2023 Oct 26. doi: 10.1111/head.14642.
    >> Share

  310. CHIANG CC
    Hypermobility spectrum disorders and migraine in adolescents.
    Headache. 2023 Oct 24. doi: 10.1111/head.14650.
    >> Share

  311. PORTT AE, Orchard C, Chen H, Ge E, et al
    Migraine and air pollution: A systematic review.
    Headache. 2023 Oct 5. doi: 10.1111/head.14632.
    >> Share

  312. LIPTON RB, Pozo-Rosich P, Orr SL, Reed ML, et al
    Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.
    Headache. 2023 Oct 5. doi: 10.1111/head.14629.
    >> Share

  313. MCCRACKEN HT, Lee AA, Smitherman TA
    Headache and psychological variables as predictors of disability in individuals with primary headache disorders.
    Headache. 2023;63:1259-1270.
    >> Share

    September 2023
  314. MD ISA NA, Tummanapalli SS, Chiang JCB, Krishnan AV, et al
    Neuropathic changes in corneal nerve endings-A potential objective biomarker for migraine frequency and response to treatment.
    Headache. 2023 Sep 23. doi: 10.1111/head.14630.
    >> Share

  315. WANG VS, Kosman J, Yuan H, Lauritsen C, et al
    Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study.
    Headache. 2023 Sep 23. doi: 10.1111/head.14636.
    >> Share

  316. KRUSE JA, Seng EK
    Changes in cognitive appraisal in a randomized controlled trial of mindfulness-based cognitive therapy for patients with migraine.
    Headache. 2023 Sep 18. doi: 10.1111/head.14627.
    >> Share

  317. SHAPIRO HFJ, Loder E, Shapiro DJ
    Association between clinician specialty and prescription of preventive medication for young adults with migraine: A retrospective cohort study.
    Headache. 2023 Sep 11. doi: 10.1111/head.14628.
    >> Share

  318. SILVA-NETO RP, Soares AA, Souza WPO, Krymchantowski AG, et al
    "Growing pains" in children and adolescents as an early symptom of migraine: A prospective study.
    Headache. 2023 Sep 6. doi: 10.1111/head.14608.
    >> Share

  319. CHARLES A
    Aura is a symptom of a migraine attack, not its cause.
    Headache. 2023 Sep 4. doi: 10.1111/head.14623.
    >> Share

  320. CLEMENTI MA, Kienzler C, Yonker M, Harmon M, et al
    Preliminary exploration of a multidimensional sleep health composite in adolescent females with frequent migraine.
    Headache. 2023 Sep 1. doi: 10.1111/head.14626.
    >> Share

  321. LIU H, Zhang S, Gong Z, Zhao W, et al
    Association between migraine and cardiovascular disease mortality: A prospective population-based cohort study.
    Headache. 2023 Sep 1. doi: 10.1111/head.14616.
    >> Share

  322. LEI X, Wei M, Wang L, Liu C, et al
    Resting-state electroencephalography microstate dynamics altered in patients with migraine with and without aura-A pilot study.
    Headache. 2023 Sep 1. doi: 10.1111/head.14622.
    >> Share

  323. TEPPER SJ, Schwedt TJ, Vo P, Thompson J, et al
    Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
    Headache. 2023 Sep 1. doi: 10.1111/head.14612.
    >> Share

  324. MACGREGOR EA, Hutchinson S, Lai H, Dabruzzo B, et al
    Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
    Headache. 2023 Sep 1. doi: 10.1111/head.14619.
    >> Share


  325. Correction to "Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labelling".
    Headache. 2023;63:1199.
    >> Share

  326. MARTINDALE C, Presson AP, Schwedt TJ, Brennan KC, et al
    Sensory hypersensitivities are associated with post-traumatic headache-related disability.
    Headache. 2023;63:1061-1069.
    >> Share

  327. FILA M, Pawlowska E, Szczepanska J, Blasiak J, et al
    Autophagy may protect the brain against prolonged consequences of headache attacks: A narrative/hypothesis review.
    Headache. 2023;63:1154-1166.
    >> Share

  328. KATSUKI M, Matsumori Y, Kawamura S, Kashiwagi K, et al
    Developing an artificial intelligence-based diagnostic model of headaches from a dataset of clinic patients' records.
    Headache. 2023;63:1097-1108.
    >> Share

    August 2023
  329. ZAMIR O, Yarns BC, Lagman-Bartolome AM, Jobanputra L, et al
    Understanding the gaps in headache and migraine treatment with psychological and behavioral interventions: A narrative review.
    Headache. 2023 Aug 28. doi: 10.1111/head.14624.
    >> Share

  330. POLK AN, Smitherman TA
    A meta-analytic review of acceptance-based interventions for migraine.
    Headache. 2023 Aug 27. doi: 10.1111/head.14614.
    >> Share

  331. RICHER L, Luu H, Martins KJB, Vu K, et al
    Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada.
    Headache. 2023 Aug 23. doi: 10.1111/head.14613.
    >> Share

  332. MATSUMORI Y, Ishida M, Iba K, Kim BK, et al
    Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.
    Headache. 2023 Aug 21. doi: 10.1111/head.14606.
    >> Share

  333. KILINC YB, Kilinc E, Danis A, Hanci F, et al
    Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1alpha are elevated in pediatric migraine attacks.
    Headache. 2023 Aug 19. doi: 10.1111/head.14618.
    >> Share

  334. ORNELLO R, Bruno F, Frattale I, Curcio G, et al
    White matter hyperintensities in migraine are not mediated by a dysfunction of the glymphatic system-A diffusion tensor imaging magnetic resonance imaging study.
    Headache. 2023 Aug 18. doi: 10.1111/head.14607.
    >> Share

  335. QIN Z, Qu H, Liang HB, Zhou Q, et al
    Altered resting-state effective connectivity of trigeminal vascular system in migraine without aura: A spectral dynamic causal modeling study.
    Headache. 2023 Aug 7. doi: 10.1111/head.14602.
    >> Share

  336. YANG L, Zhou Y, Zhang L, Wang Y, et al
    Aryl hydrocarbon receptors improve migraine-like pain behaviors in rats through the regulation of regulatory T cell/T-helper 17 cell-related homeostasis.
    Headache. 2023 Aug 4. doi: 10.1111/head.14599.
    >> Share

    July 2023
  337. NAHMAN-AVERBUCH H, Callahan D, Darken R, Haroutounian S, et al
    Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment-A narrative review.
    Headache. 2023 Jul 31. doi: 10.1111/head.14601.
    >> Share

  338. GELFAND AA, Allen IE, Grimes B, Irwin S, et al
    Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.
    Headache. 2023 Jul 19. doi: 10.1111/head.14600.
    >> Share

  339. MEHNERT J, Fischer-Schulte L, May A
    Aura phenomena do not initiate migraine attacks-Findings from neuroimaging.
    Headache. 2023 Jul 14. doi: 10.1111/head.14597.
    >> Share

  340. DE VRIES LENTSCH S, Perenboom MJL, Carpay JA, MaassenVanDenBrink A, et al
    Visual hypersensitivity in patients treated with anti-calcitonin gene-related peptide (receptor) monoclonal antibodies.
    Headache. 2023;63:926-933.
    >> Share

  341. REIDY BL, Riddle EJ, Powers SW, Slater SK, et al
    Biopsychosocial treatment response among youth with continuous headache: A retrospective, clinic-based study.
    Headache. 2023;63:942-952.
    >> Share

    June 2023
  342. LANE IA, Zempsky WT
    Capturing the experiences of sexual and gender minorities with migraine headache.
    Headache. 2023 Jun 27. doi: 10.1111/head.14595.
    >> Share

  343. JICHA CJ, Alex A, Herskovitz S, Haut SR, et al
    Migraine with prolonged aphasic aura associated with a CACNA1A mutation: A case report and narrative review.
    Headache. 2023 Jun 27. doi: 10.1111/head.14594.
    >> Share

  344. NAGRI A, Patel M, Mwansisya T, Adebayo PB, et al
    Development and initial validation of the Kiswahili version of the Migraine Disability Assessment (MIDAS-K) questionnaire.
    Headache. 2023 Jun 27. doi: 10.1111/head.14592.
    >> Share

  345. DANNO D, Ishizaki K, Kikui S, Takeshima T, et al
    Treatment of hemiplegic migraine with anti-calcitonin gene-related peptide monoclonal antibodies: A case series in a tertiary-care headache center.
    Headache. 2023 Jun 27. doi: 10.1111/head.14591.
    >> Share

  346. BOCZARSKA-JEDYNAK M, Blumenfeld AM
    Injection technique of the upper face with onabotulinumtoxinA in chronic migraine.
    Headache. 2023 Jun 27. doi: 10.1111/head.14588.
    >> Share

  347. PERETZ A, Stark-Inbar A, Harris D, Tamir S, et al
    Safety of remote electrical neuromodulation for acute migraine treatment in pregnant women: A retrospective controlled survey-study.
    Headache. 2023 Jun 19. doi: 10.1111/head.14586.
    >> Share

  348. RODRIGUEZ-RIVAS R, Moreno-Martinez CA, Cerqueira TL, Enriquez-Peregrino KG, et al
    Translation, cross-cultural adaptation, and validation of a Latin American Spanish version of the ID Migraine screening test.
    Headache. 2023 Jun 16. doi: 10.1111/head.14509.
    >> Share

  349. MANGANO GD, Capizzi MR, Mantuano E, Veneziano L, et al
    Familial hemiplegic migraine in pediatric patients: A genetic, clinical, and follow-up study.
    Headache. 2023 Jun 16. doi: 10.1111/head.14582.
    >> Share

  350. COHEN F, Bobker S
    From diet to disasters, lifestyle factors can affect headaches and migraine.
    Headache. 2023 Jun 15. doi: 10.1111/head.14500.
    >> Share

  351. AHMED Z, Honomichl R, Thompson SF, Cohen JM, et al
    Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
    Headache. 2023 Jun 14. doi: 10.1111/head.14527.
    >> Share

  352. YU B, Hou S, Xing Y, Jia Z, et al
    Ultrasound-guided stellate ganglion block for the treatment of migraine in elderly patients: A retrospective and observational study.
    Headache. 2023 Jun 14. doi: 10.1111/head.14537.
    >> Share

  353. TEPPER SJ, Lipton RB, Silberstein SD, Kudrow D, et al
    Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Headache. 2023 Jun 14. doi: 10.1111/head.14536.
    >> Share

  354. SENG EK, Parker A, Shapiro RE, Buse DC, et al
    Living in society, living with migraine: Editorial for the 2022 Members' Choice Award paper.
    Headache. 2023 Jun 14. doi: 10.1111/head.14530.
    >> Share

  355. ZLOOF Y, Simchoni M, Derazne E, Tsur AM, et al
    Hypermobility spectrum disorders and active migraine in Israeli adolescents: A nationwide study.
    Headache. 2023 Jun 14. doi: 10.1111/head.14526.
    >> Share

  356. ZHANG Y, Smith JH, Mullan AF, Vanmeter DE, et al
    Frequency of headache in emergency department patients with anaphylaxis: A cross-sectional study.
    Headache. 2023;63:834-838.
    >> Share

  357. KARSAN N, Bose RP, O'Daly O, Zelaya F, et al
    Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labeling.
    Headache. 2023;63:771-787.
    >> Share

  358. PARK SY, Kim J
    Characteristics of patients who visited emergency departments for headache in South Korea: A descriptive cross-sectional study.
    Headache. 2023;63:795-804.
    >> Share

    May 2023
  359. SACCA F, Braca S, Sansone M, Miele A, et al
    A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Headache. 2023 May 31. doi: 10.1111/head.14528.
    >> Share

  360. LAU CI, Chen WH, Wang HC, Walsh V, et al
    Decision-making impairment under ambiguity but not under risk may underlie medication overuse in patients with chronic migraine.
    Headache. 2023 May 26. doi: 10.1111/head.14513.
    >> Share

  361. HANS A, Stonnington CM, Zhang N, Butterfield R, et al
    The impact of resilience on headache disability as measured by the Migraine Disability Assessment (MIDAS).
    Headache. 2023 May 23. doi: 10.1111/head.14518.
    >> Share

  362. LIPTON RB, Sico J, Seng EK
    Migraine screening in English and Spanish.
    Headache. 2023 May 4. doi: 10.1111/head.14520.
    >> Share

  363. MANGRUM R, Gerstein MT, Hall CJ 3rd, Buse DC, et al
    Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine.
    Headache. 2023 May 4. doi: 10.1111/head.14521.
    >> Share

  364. KELLIER DJ, de Prado BM, Haagen D, Grabner P, et al
    Validity of self-reported migraine in adolescents and children.
    Headache. 2023 May 4. doi: 10.1111/head.14498.
    >> Share

  365. TEPPER SJ, Dong Y, Vincent M, Wietecha LA, et al
    Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
    Headache. 2023 May 3. doi: 10.1111/head.14494.
    >> Share

  366. MEI HR, Hu YY, Kapadia S, Ouimet T, et al
    Efficacy of dual enkephalinase inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors.
    Headache. 2023;63:621-633.
    >> Share

  367. ACKLEY E, Asamoah P, Mirsky D, White C, et al
    Dots and spots: A retrospective review of T2-hyperintense white matter lesions in pediatric patients with and without headache.
    Headache. 2023;63:611-620.
    >> Share

  368. HOULE TT, Smith MR, Turner DP
    Common challenges in the development of prediction models.
    Headache. 2023;63:569-570.
    >> Share

  369. KATSUKI M, Tatsumoto M, Kimoto K, Iiyama T, et al
    Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross-sectional study.
    Headache. 2023;63:585-600.
    >> Share

    April 2023
  370. WANG Z, Lin Q, Peng YB
    Multi-region local field potential signatures and brain coherence alternations in response to nitroglycerin-induced migraine attacks.
    Headache. 2023 Apr 10. doi: 10.1111/head.14506.
    >> Share

  371. CHEN YJ, Hu KF, Chan C, Huang C, et al
    Association of periodontal disease with migraine: A large-scale community-based cross-sectional study.
    Headache. 2023 Apr 10. doi: 10.1111/head.14491.
    >> Share

  372. CARMILLO L, Fasano A
    Fremanezumab plus plasmapheresis in a patient with chronic migraine and myasthenia gravis: Case report of an effective treatment.
    Headache. 2023 Apr 10. doi: 10.1111/head.14497.
    >> Share

  373. THOMPSON AC, Goodbourn PT, Forte JD
    Perceived severity of Visual Snow Syndrome is associated with visual allodynia.
    Headache. 2023;63:494-505.
    >> Share

    March 2023
  374. OLIVEIRA FAA, Dourado-Filho MG, Sampaio Rocha-Filho PA
    Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study.
    Headache. 2023 Mar 29. doi: 10.1111/head.14492.
    >> Share

  375. DIGRE KB
    Good New? Bad News? Idiopathic intracranial hypertension and migraine.
    Headache. 2023 Mar 29. doi: 10.1111/head.14489.
    >> Share

  376. GRAF M, Kim E, Brewer I, Hernandez J, et al
    Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panel.
    Headache. 2023 Mar 15. doi: 10.1111/head.14479.
    >> Share

  377. GERSTEIN MT, Wirth RJ, Uzumcu AA, Houts CR, et al
    Patient-reported experiences with migraine-related cognitive symptoms: Results of the MiCOAS qualitative study.
    Headache. 2023 Mar 10. doi: 10.1111/head.14484.
    >> Share

  378. VERHAGEN IE, van der Arend BWH, van Casteren DS, le Cessie S, et al
    Sex differences in migraine attack characteristics: A longitudinal E-diary study.
    Headache. 2023;63:333-341.
    >> Share

  379. KUDROW D, Dafer R, Dodick DW, Starling A, et al
    Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data.
    Headache. 2023;63:418-428.
    >> Share

  380. BASEDAU H, Oppermann T, Gundelwein Silva E, Peng KP, et al
    Characterization of trigeminal C-fiber reactivity through capsaicin-induced release of calcitonin gene-related peptide.
    Headache. 2023;63:353-359.
    >> Share

  381. ACKLEY E, Gibler RC, Orr SL, Powers SW, et al
    Virtual issue: Recent advances in pediatric headache: Bridging the data gap.
    Headache. 2023;63:305-306.
    >> Share

    February 2023
  382. ESTAVE PM, Margol C, Beeghly S, Anderson R, et al
    Mechanisms of mindfulness in patients with migraine: Results of a qualitative study.
    Headache. 2023 Feb 28. doi: 10.1111/head.14481.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016